Navigation Links
Debiopharm Group™ Presents the 'Debiopharm Group™ Life Sciences Award 2011' and two 'Junior Debiopharm Group™ Awards 2011' at the ISREC 2011 Life Sciences Symposium
Date:9/8/2011

ly at the stage of late postdoctoral studies or launching an independent research group. The selection criteria are based on excellence in previous work and originality of future projects.

Professor Meylan has just been appointed tenure-track Professor at the EPFL, following his postdoctoral work in the laboratory of Professor Tyler Jacks at MIT. His laboratory at the EPFL focuses on developing mouse models of lung cancer to test new promising anti-cancer compounds.

Doctor Busskamp recently completed a spectacular Ph.D. thesis in applied neuroscience at the FMI (Dr. Botond Roska's laboratory). During his Ph.D., he developed and validated a new type of therapy to repair blind retinas in vivo.

"Today's nominees all provided high quality and innovative work, allowing the jury to reach a unanimous decision," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. "We are happy to recognise and reward these young scientists for their accomplishments. We wish them all the best and hope their research will lead to major discoveries in the medical field in the years to come."

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trial
'/>"/>

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized and ... 29-30 in San Francisco, CA. This year’s conference brings ... and clinicians focused on addressing and solving the significant ... twelve years since the sequencing of the human genome, ... pharmacogenetic information in the label and molecular diagnostics have ...
(Date:8/20/2014)... , Aug. 20, 2014 /PRNewswire-iReach/ -- A ... transformative collaboration between the school,s bioengineering department and ... of the Intel® Software Academic Program, UCSD,s research ... and the human body.  Photo ... study exhibits the work of Dr. Todd ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 WriteResult®, a ... today that it has expanded its myPROpad™ ePRO tablet ... EQ-5D-5L, one of the most widely used and ... general health status. The EQ-5D is used during clinical ... a measure that can be used to demonstrate Health-Related ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2
... hasn't felt a down economy at all. PHC Consulting is focused ... (laboratory clinical and research, physician call points, medical devices, pharmaceutical, etc). ... attributes that growth to a strong web presence. , ... ...
... BioTime’s wholly-owned subsidiary Embryome Sciences, Inc., have ... International Stem Cell Corporation (OTCBB:ISCO) through its ... jointly produce and distribute hundreds of new ... along with corresponding data and reagents. The ...
... /PRNewswire-FirstCall/ - Quest PharmaTech Inc.,(TSX-V: QPT), ("Quest" or ... I/II clinical study designed to investigate appropriate,treatment parameters ... for hair removal applications. The interim results represent ... targeted 100-patient clinical,trial., "The Phase I/II interim ...
Cached Biology Technology:Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 3 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 4 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 5Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal 2Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal 3
(Date:8/21/2014)... Conn. , Aug. 21, 2014 Nxt-ID, ... the growing mobile commerce market, announced today that its ... common stock to be issued in its proposed underwritten ... approved for listing on The Nasdaq Capital Market, subject ... the common stock and warrants, and will trade under ...
(Date:8/21/2014)... ubiquitous skin fungus linked to dandruff, eczema and other ... to even further global reachesincluding Hawaiian coral reefs and ... vents. , A review in the scientific journal ... of the fungi of the genus Malassezia ... sequencing datasets from around the world. , University of ...
(Date:8/21/2014)... Nine researchers from Beth Israel Deaconess Medical Center (BIDMC ... World,s Most Influential Scientific Minds 2014," a comprehensive ... a web resource for science metrics and research performance ... the most influential "are performing and publishing work that ... their science," according to a Thomson Reuters statement. Researchers ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... creating a better way to see molecules at work in ... Learning and Memory and the MIT Department of Chemistry are ... also help further understanding of how synapses go awry in ... study will appear in the Oct. 7 issue of ...
... survival rates. Yet, one of the deadliest cancers in ... detect in its early stages. Now, researchers have ... shining diffuse light on cells swabbed from patients, cheeks. ... partial wave spectroscopic (PWS) microscopy--was able to differentiate individuals ...
... make life tougher for farmers and ranchers who live in ... why not turn the plants into fuel and make some ... alone could supply biomass far into the future, according to ... to fuel is an intriguing idea that,s being investigated by ...
Cached Biology News:MIT researchers develop a better way to see molecules at work in living brain cells 2Cheek swab may detect lung cancer 2Cheek swab may detect lung cancer 3Montana State, partners in 6 states consider converting invasive plants to fuel 2Montana State, partners in 6 states consider converting invasive plants to fuel 3Montana State, partners in 6 states consider converting invasive plants to fuel 4
... through the extracellular matrix (ECM) is an ... cells initiate invasion by adhering to and ... Proteolytic enzymes, such as MMP collagenases, dissolve ... membrane) surrounding the blood vessels to allow ...
... The InnoCyte Laminin-Based 96-well Cell Invasion ... capacity of cells using laminin as a ... potential anti-metastatic agents in vitro in a ... pore size is appropriate for all types ...
... kit allows for quick and reproducible immunoprecipitation (IP) ... system is more reproducible than regular IPs, which ... A/G agarose without disrupting the agarose bed. The ... Release is reversible, and elution of the immune ...
... are designed for the study of protein:protein ... method. Proteins that interact with GST•Tag™, ... are copurified using affinity resins for the ... a spin filter. The complexes are eluted ...
Biology Products: